The global anxiety and depression treatment market value stood at $17,770.9 million in 2020, and it is predicted to surge to $24,467.7 million by 2030. According to the estimates of the market research company, P&S Intelligence, the market will advance at a CAGR of 3.3% from 2021 to 2030 (forecast period). The market is being driven by the surging population of geriatric people, growing public awareness about mental illnesses and their treatment procedures, and soaring number of product approvals around the world.
According to the World Population Ageing 2020 report published by the United Nations Department of Economic and Social Affairs (UNDESA), the population of people aged 65 years or above will rise from 727 million in 2020 to more than 1.5 billion by 2050. As geriatric people go through several stress conditions and are highly vulnerable to anxiety and depression, owing to their reduced socioeconomic conditions after retirement and isolation and loneliness, their ballooning population is positively impacting the worldwide demand for anxiety and depression treatment products.
Request for sample pages of this report: https://www.psmarketresearch.com/market-analysis/anxiety-and-depression-treatment-market/report-sample
The other major anxiety and depression treatment market growth driver is the growing public awareness about mental diseases all over the world. Many public and private healthcare institutions are launching initiatives for raising public awareness of various mental illnesses and their treatment procedures. For instance, the World Health Organization (WHO) has declared 10th October as the World Mental Health Day to raise awareness, increase accessibility to services, provide treatment and support for mental health issues, and mitigate the stigma associated with these diseases.
Depending on product type, the market is divided into devices and drugs. Between these, the drugs category held the larger share in the market in the past. This was primarily because of the increasing implementation of government initiatives for raising mental health awareness and knowledge of associated illnesses and the surging number of clinical trials being conducted by research institutes for developing advanced drugs. This is subsequently expanding the portfolio of anxiety and depression drugs, which is, in turn, attracting a large number of healthcare professionals and patients.
Geographically, the Asia-Pacific (APAC) region is expected to be the fastest-growing region in the anxiety and depression treatment market during the forecast period. This is credited to factors, such as the mushrooming population of geriatric people, increasing age-related risks like anxiety and depression, and rising prevalence of depression among young individuals in the region. As per the United Nations Population Fund (UNFPA), one out of every four individuals in the APAC region will be above 60 years of age by 2050. Additionally, the population of people aged 60 years and above will triple between 2010 and 2050 and reach 1.3 billion.
Browse detailed report on Global Anxiety and Depression Treatment Market Analysis and Growth Forecast to 2030
Hence, it can be safely said that the demand for anxiety and depression treatment products will soar in the coming years, primarily because of the rising incidence of depression and anxiety, growing public awareness about mental health diseases and their treatment procedures, and ballooning population of geriatric people all over the world.
Anxiety and Depression Treatment Market Size Breakdown by Segment
By Product Type
- Drugs
- Antidepressants
- SSRIs
- SNRIs
- TCAs
- MAOIs
- Others (atypical antidepressants and noradrenergic and specific serotonergic antidepressants [NaSSAs])
- Anticonvulsants
- Atypical antipsychotics
- Benzodiazepines
- Beta-blockers
- Devices
By Disorder Type
- Major Depressive Disorder
- OCD
- Phobia
- PTSD
- Others (persistent depressive disorder, atypical depression, premenstrual dysphoric disorder, bulimia, and hot flashes caused by menopause)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
- Direct Channels
By Region
- North America Anxiety and Depression Treatment Market
- By product type
- By disorder type
- By distribution channel
- By country – U.S. and Canada
- U.S. anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- Canada anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- Europe Anxiety and Depression Treatment Market
- By product type
- By disorder type
- By distribution channel
- By country – Germany, France, U.K., Italy, Spain, and Rest of Europe
- Germany anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- France anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- U.K. anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- Italy anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- Spain anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- Asia-Pacific (APAC) Anxiety and Depression Treatment Market
- By product type
- By disorder type
- By distribution channel
- By country – China, Japan, India, Australia, South Korea, and Rest of APAC
- China anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- Japan anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- India anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- Australia anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- South Korea anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- Latin America (LATAM) Anxiety and Depression Treatment Market
- By product type
- By disorder type
- By distribution channel
- By country – Brazil, Mexico, and Rest of LATAM
- Brazil anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- Mexico anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- Middle East and Africa (MEA) Anxiety and Depression Treatment Market
- By product type
- By disorder type
- By distribution channel
- By country – Saudi Arabia, South Africa, and Rest of MEA
- Saudi Arabia anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
- South Africa anxiety and depression treatment market
- By product type
- By disorder type
- By distribution channel
Browse More Reports
Sleep Aids Market - Globally, the sleep aids market will expand sharply in North America in the forthcoming years, as per the estimates of P&S Intelligence. This will be due to the increasing prevalence of sleep disorders and growing implementation of initiatives by several government and non-government organizations for raising public awareness about sleep hygiene and sleep disorders in the region.
Generic Drugs Market - Geographically, Asia-Pacific (APAC) led the generic drugs market in the recent past and it is expected to retain its dominance in the foreseeable future as well. This can be primarily attributed to the soaring geriatric population, mounting healthcare expenditure, growing prevalence of chronic diseases, and rising implementation of government initiatives aimed at promoting the use of generic drugs in the region.
Media Contact
Company Name: P&S Intelligence
Contact Person: Abhishek
Email:Send Email
Phone: +918887787886
Address:Noida Sector 2
City: Noida
State: UP
Country: India
Website: https://www.psmarketresearch.com/market-analysis/anxiety-and-depression-treatment-market
